bendamustine hydrochloride has been researched along with EBV Infections in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiba, S; Hasegawa, Y; Kurita, N; Maie, K; Muroi, K; Noguchi, M; Obara, N; Sakata-Yanagimoto, M; Sato, T; Yokoyama, Y | 1 |
| Kwong, YL; Poon, LM | 1 |
2 other study(ies) available for bendamustine hydrochloride and EBV Infections
| Article | Year |
|---|---|
Late occurrence of Epstein-Barr virus-associated lymphoproliferative disorder in a patient with follicular lymphoma treated with bendamustine and rituximab.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Epstein-Barr Virus Infections; Female; Herpesvirus 4, Human; Humans; Lymphoma, Follicular; Middle Aged; Rituximab | 2015 |
Complete remission of refractory disseminated NK/T cell lymphoma with brentuximab vedotin and bendamustine.
Topics: Adolescent; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Brentuximab Vedotin; Combined Modality Therapy; Drug Resistance, Neoplasm; Epstein-Barr Virus Infections; Female; Hematopoietic Stem Cell Transplantation; Herpesvirus 4, Human; Humans; Immunoconjugates; Immunophenotyping; Ki-1 Antigen; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Remission Induction; RNA, Viral; Salvage Therapy; Skin Neoplasms; Tumor Virus Infections | 2016 |